Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that finasteride treatment was more effective in treating prostatitis-related hemospermia compared to non-prostatitis cases, particularly after excluding sonographically abnormal cases.

Dutasteride may help prevent prostate cancer, but more research is needed.

Combining different treatments may be needed to effectively manage chronic prostatitis.

This study found that ureteroileal anastomosis with direct intraluminal visualization had a 4.2% stricture rate, which compares favorably to other techniques with rates between 3.5% and 11.1%.

This news section reviews recent findings in cancer research, including a study confirming finasteride's ability to reduce prostate cancer risk without raising mortality, but reports no new clinical results itself.

This study found a significant association between male breast cancers and exposure to finasteride and dutasteride, with an estimated additional case per 564 men taking these drugs.

This review discusses the stratification and management of male patients with lower urinary tract symptoms and benign prostatic hyperplasia in primary care and reports no new clinical results.

This study found that dutasteride more effectively reduced serum dihydrotestosterone levels than finasteride in patients with benign prostatic hyperplasia.

This review discusses various treatment recommendations for Chronic Prostatitis/Chronic Pelvic Pain Syndrome, noting the need for further trials on herbal therapies and specific indications for surgical intervention, but reports no new clinical results.

This study will explore whether combination therapy with either dutasteride or finasteride and an α1 blocker is more effective than monotherapy for treating BPH, but it reports no new results.

Finasteride is safe for long-term use in prostate cancer treatment.

This study found that finasteride does not increase the risk of high-grade prostate cancer but instead improves the prostate-specific antigen test's sensitivity to detect such cancers.

This Cochrane review reports that 5-alpha reductase inhibitors may slightly reduce urological symptoms and acute urinary retention risk compared to placebo, with a possible small reduction in surgical intervention need compared to alpha blockers.

This systematic review evaluated the efficacy and safety of dutasteride in men with benign prostatic hyperplasia and found that dutasteride significantly reduced the need for prostate surgery and acute urinary retention episodes compared to finasteride, with no significant difference in safety profiles between the two.

Cyproterone and finasteride reduced hypersexuality but caused serious side effects.

This review discusses the pharmacology and clinical use of finasteride for benign prostatic hyperplasia and reports its effectiveness in reducing prostate size and symptoms, though success varies among patients.

This review analyzes existing literature on prognostic factors for renal cell carcinoma, highlighting the need for continuous updates of prognostic models to reflect advancement in molecular pathway knowledge and targeted therapies.

Finasteride lowers prostate cancer risk but may increase high-grade tumors and sexual side effects.

This review discusses the potential of phytochemicals from plants as alternative treatments for prostate cancer, highlighting their possible benefits over current 5-alpha-Reductase inhibitors, but reports no new findings.

This review discusses the role of 5α-reductase in prostate development and BPH, and reports no new clinical results; ongoing trials are exploring dual isozyme inhibitors for improved treatment efficacy.

This study found that Epristeride and Finasteride reduced prostate development and testis weight in male rats, but only Finasteride appeared to impact reproductive function.

This review summarizes a meta-analysis suggesting that finasteride is most effective for improving symptoms and urinary flow in men with large prostates experiencing benign prostatic hyperplasia.

This article reviews the impact of 5α-reductase inhibitors on prostate cancer detection and mortality but provides no new clinical results.

This study found that among men with Benign Prostatic Hyperplasia, treatment with the 5α-reductase inhibitor finasteride for three months significantly reduced levels of dihydrotestosterone and estradiol, hormones involved in prostate enlargement, without altering follicle-stimulating hormone or luteinizing hormone levels.

This study found that the detection rate of clinically insignificant prostate cancer increases with the number of repeat prostate biopsies in patients with persistently suspicious prostate cancer.

This editorial comment in the Journal of Urology discusses the implications of the Prostate Cancer Prevention Trial but reports no new research findings.

The journal retracted an article due to inaccurate statistics and asked the authors to revise and resubmit it.

This study found that Sonirid Duo, a combination of tamsulosin and finasteride, significantly improved symptoms and quality of life in patients with BPH over 12 months.